Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

2.

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.

Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL.

Nat Commun. 2017 Aug 22;8(1):319. doi: 10.1038/s41467-017-00388-9.

3.

Identification of competing endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic approach.

Zarringhalam K, Tay Y, Kulkarni P, Bester AC, Pandolfi PP, Kulkarni RV.

Sci Rep. 2017 Aug 10;7(1):7755. doi: 10.1038/s41598-017-08209-1.

4.

Novel therapeutic strategies in the treatment of triple-negative breast cancer.

Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM.

Ther Adv Med Oncol. 2017 Jul;9(7):493-511. doi: 10.1177/1758834017711380. Epub 2017 Jun 13. Review.

5.

CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.

Stefansson OA, Hermanowicz S, van der Horst J, Hilmarsdottir H, Staszczak Z, Jonasson JG, Tryggvadottir L, Gudjonsson T, Sigurdsson S.

BMC Cancer. 2017 Jul 5;17(1):469. doi: 10.1186/s12885-017-3453-8.

6.

PTEN, Longevity and Age-Related Diseases.

Tait IS, Li Y, Lu J.

Biomedicines. 2013 Dec 13;1(1):17-48. doi: 10.3390/biomedicines1010017. Review.

7.

Effect of Helix aspersa extract on TNFα, NF-κB and some tumor suppressor genes in breast cancer cell line Hs578T.

El Ouar I, Braicu C, Naimi D, Irimie A, Berindan-Neagoe I.

Pharmacogn Mag. 2017 Apr-Jun;13(50):281-285. doi: 10.4103/0973-1296.204618. Epub 2017 Apr 18.

8.

PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.

Gupta A, Anjomani-Virmouni S, Koundouros N, Dimitriadi M, Choo-Wing R, Valle A, Zheng Y, Chiu YH, Agnihotri S, Zadeh G, Asara JM, Anastasiou D, Arends MJ, Cantley LC, Poulogiannis G.

Mol Cell. 2017 Mar 16;65(6):999-1013.e7. doi: 10.1016/j.molcel.2017.02.019.

9.

Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.

Chen L, Jenjaroenpun P, Pillai AM, Ivshina AV, Ow GS, Efthimios M, Zhiqun T, Tan TZ, Lee SC, Rogers K, Ward JM, Mori S, Adams DJ, Jenkins NA, Copeland NG, Ban KH, Kuznetsov VA, Thiery JP.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2215-E2224. doi: 10.1073/pnas.1701512114. Epub 2017 Mar 1.

10.

PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients

Elwy F, Helwa R, El Leithy AA, Shehab El din Z, Assem MM, Hassan NH.

Asian Pac J Cancer Prev. 2017 Jan 1;18(1):57-64.

11.

Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.

Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.

J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.

12.

Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression.

Rangel R, Lee SC, Hon-Kim Ban K, Guzman-Rojas L, Mann MB, Newberg JY, Kodama T, McNoe LA, Selvanesan L, Ward JM, Rust AG, Chin KY, Black MA, Jenkins NA, Copeland NG.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7749-E7758. Epub 2016 Nov 14.

13.

Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.

Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK, Kim SW.

Curr Oncol. 2016 Oct;23(5):298-303. Epub 2016 Oct 25.

14.

On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer.

Penkert J, Ripperger T, Schieck M, Schlegelberger B, Steinemann D, Illig T.

Oncotarget. 2016 Oct 11;7(41):67626-67649. doi: 10.18632/oncotarget.11759. Review.

15.

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH.

BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2.

16.

PTEN regulates PLK1 and controls chromosomal stability during cell division.

Zhang Z, Hou SQ, He J, Gu T, Yin Y, Shen WH.

Cell Cycle. 2016 Sep 16;15(18):2476-85. doi: 10.1080/15384101.2016.1203493. Epub 2016 Jul 11.

17.

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.

Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V.

Cancer Cell Int. 2016 Jul 1;16:53. doi: 10.1186/s12935-016-0333-2. eCollection 2016.

18.

Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism.

Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK.

JCI Insight. 2016 May 5;1(6). pii: e87030.

19.

Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.

Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.

Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.

20.

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.

Mabuchi S, Sugiyama T, Kimura T.

J Gynecol Oncol. 2016 May;27(3):e31. doi: 10.3802/jgo.2016.27.e31. Review.

Supplemental Content

Support Center